Authors:
Address: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA. ishui@hsph.harvard.edu
Journal:

Publication:

abstract

CONTEXT:

Current rotavirus vaccines were not associated with intussusception in large prelicensure trials. However, recent postlicensure data from international settings suggest the possibility of a low-level elevated Risk, primarily in the first week after the first vaccine dose.

OBJECTIVE:

To examine the risk of intussusception following pentavalent rotavirus vaccine (RV5) in US infants.

DESIGN, SETTING, AND PATIENTS:

This cohort study included infants 4 to 34 weeks of age, enrolled in the Vaccine Safety Datalink (VSD) who received RV5 from May 2006-February 2010. We calculated standardized incidence ratios (SIRs), relative risks (RRs), and 95% confidence intervals for the association between intussusception and RV5 by comparing the rates of intussusception in infants who had received RV5 with the rates of intussusception in infants who received other recommended vaccines without concomitant RV5 during the concurrent period and with the expected number of intussusception visits based on background rates assessed prior to US licensure of the RV5 (2001-2005).

MAIN OUTCOME MEASURE:

Intussusception occurring in the 1- to 7-day and 1- to 30-day risk windows following RV5 vaccination.

RESULTS:

During the study period, 786,725 total RV5 doses, which included 309,844 first doses, were administered. We did not observe a statistically significant increased risk of intussusception with RV5 for either comparison group following any dose in either the 1- to 7-day or 1- to 30-day risk window. For the 1- to 30-day window following all RV5 doses, we observed 21 cases of intussusception compared with 20.9 expected cases (SIR, 1.01; 95% CI, 0.62-1.54); following dose 1, we observed 7 cases compared with 5.7 expected cases (SIR, 1.23; 95% CI, 0.5-2.54). For the 1- to 7-day window following all RV5 doses, we observed 4 cases compared with 4.3 expected cases (SIR, 0.92; 95% CI, 0.25-2.36); for dose 1, we observed 1 case compared with 0.8 expected case (SIR, 1.21; 95% CI, 0.03-6.75). The upper 95% CI limit of the SIR (6.75) from the historical comparison translates to an upper limit for the attributable risk of 1 intussusception case per 65,287 RV5 dose-1 recipients.

CONCLUSION:

Among US infants aged 4 to 34 weeks who received RV5, the risk of intussusception was not increased compared with infants who did not receive the rotavirus vaccine.

Related Articles
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.
Pediatrics. 2008
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.
Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, et al. Pediatrics. 2008 Jun; 121(6):1206-12.
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program. Rep Carcinog Backgr Doc. 2010 Jan; (10-5981):i-512.
Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
Pediatrics. 2010
Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Pediatrics. 2010 Feb; 125(2):e208-13. Epub 2010 Jan 25.
Review Rotavirus live, oral, pentavalent vaccine.
Clin Ther. 2007
Review Rotavirus live, oral, pentavalent vaccine.
Tom-Revzon C. Clin Ther. 2007 Dec; 29(12):2724-37.
Review Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Cochrane Database Syst Rev. 2012
Review Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N. Cochrane Database Syst Rev. 2012 Feb 15; 2:CD008521. Epub 2012 Feb 15.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster